Bill Burkoth is a managing partner at SVB Capital, responsible for the Life Science and Healthcare Practice, bringing more than 20 years of life science venture capital (VC) investing and startup experience to the practice.
Before joining SVB Capital, Bill was an executive director in worldwide business development and a senior partner and founding member of Pfizer Ventures, the venture capital arm of Pfizer Inc. During his 17-year tenure with Pfizer Ventures, Bill sourced and led dozens of venture investments in life science companies across biotechnology, medical devices and tools and diagnostics. Bill played an instrumental role in numerous successful VC investments, including 4D Molecular Therapeutics (Nasdaq: FDMT), Avid Radiopharmaceuticals (acquired by Eli Lilly), Clovis Oncology (Nasdaq: CLVS), DVS Sciences (acquired by Fluidigm), Evolution Benefits (acquired by Genstar Capital), HandyLab (acquired by Becton Dickinson), NeuMoDx (acquired by QIAGEN) and Novocure (Nasdaq: NVCR). Additionally, he managed international investment partnerships in several overseas markets, including China, Brazil and Africa.
Bill holds a bachelor’s degree in chemistry from Whitman College and a master’s in business administration from Columbia University. He currently serves on the board of directors of 4D Molecular Therapeutics.
Bill lives in the New York tri-state area with his wife and two sons.